2025
Timing of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study
Dribin T, Sampson H, Zhang Y, Boyd S, Zhang N, Michelson K, Neuman M, Brousseau D, Mistry R, Freedman S, Aronson P, Bergmann K, Boswell B, Chinta S, Chua W, Cohen A, Cohen J, Daggett A, Davis J, Freeman J, Khanna K, Knoles C, Kwan K, Larsen C, Lee J, Lubell T, Metcalf A, Moake M, Nesiama J, Ngo T, Pulcini C, Russo C, Singh N, Srivastava G, Strutt J, Thapar V, Vander Wyst C, Walsh P, Wolnerman Y, Schnadower D, Academy of Pediatrics P, Kanngiesser A, McGarghan F, Dulchavsky A, Costalez J, DesPain A, Armanious M, Haghnazarian E, Brown-Whitehorn T, Weigert R, Dayan P, Meltzer J, Chowdhury N, Benedetti J, Sinziana C, Handorf A, Ruthford M, Devens M, Mecham C, Holland J, Casas T, Brown J, Panda P, Morrow A, Maready M, Nathani Y, Stevens M, Abraham G, Yen K, Cooper-Sood J, Woolf S. Timing of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study. The Lancet Child & Adolescent Health 2025, 9: 484-496. PMID: 40506197, DOI: 10.1016/s2352-4642(25)00139-7.Peer-Reviewed Original ResearchConceptsElectronic medical recordsEmergency departmentRetrospective cohort studyCohort studyMedical recordsDocumentation of symptomsCardiovascular involvementHealth-care facilitiesEpinephrine doseAcute allergic reactionsNational Institutes of HealthCumulative incidenceNational Center for Advancing Translational SciencesInstitutes of HealthChildren Aged 6 MonthsClinical ModificationHospital wardsIncidence rateICD-10Observation periodPrimary outcomeAllergic reactionsSecondary to medicationsInitiation to discontinuationKaplan-Meier analysisEpidemiology of Neuroendocrine Neoplasms in the US
Dasari A, Wallace K, Halperin D, Maxwell J, Kunz P, Singh S, Chasen B, Yao J. Epidemiology of Neuroendocrine Neoplasms in the US. JAMA Network Open 2025, 8: e2515798. PMID: 40553474, PMCID: PMC12188367, DOI: 10.1001/jamanetworkopen.2025.15798.Peer-Reviewed Original ResearchConceptsDuration prevalenceIncidence rateNational Cancer Institute's SurveillanceNeuroendocrine neoplasmsOverall survivalNeuroendocrine tumorsAge-adjusted incidenceSurvival trends of patientsAnnual age-adjusted incidenceNeuroendocrine neoplasm casesCross-sectional studyHighest incidence ratePrimary siteTrends of patientsInstitute's SurveillanceMain OutcomesPrevalence of neuroendocrine neoplasmsSmall bowelPrimary site of originFactors associated with survivalDiagnosis of early stage diseasePractice patternsPancreatic neuroendocrine tumorsGastrointestinal neuroendocrine tumorsEarly stage diseaseCancer care for adolescents and young adults under the age of 50 in Saudi Arabia: policy review, research gaps, and future directions
Alessy S, Alghamdi M, Al-Bawardy B, Alghamdi S, Al-Hamoudi W, Alomaim W, Abaalkhail F, Alqarni A, Alsharm A, Alqurashi Y, Bokhary M, Alqahtani S. Cancer care for adolescents and young adults under the age of 50 in Saudi Arabia: policy review, research gaps, and future directions. EClinicalMedicine 2025, 103188. DOI: 10.1016/j.eclinm.2025.103188.Peer-Reviewed Original ResearchCancer incidence ratesPatient-centred careIncreasing cancer incidence ratesPublic health challengeYoung adultsSurvivorship carePsychological Well-BeingCancer carePsychosocial needsCare providersCancer ratesYears of ageHealthcare institutionsHealth challengesIncidence rateAYACareSaudi ArabiaUnified treatment protocolRisk factorsPolicy developmentPolicy reviewResearch initiativesTargeted researchAdultsNational Estimates and Outcomes for Supplemental Home Oxygen Therapy Injuries—A Burn Care Quality Platform Analysis
Sheckter C, Stanton E, Klas K, Phillips B, Coffey R, Savetamal A, Wibbenmeyer L. National Estimates and Outcomes for Supplemental Home Oxygen Therapy Injuries—A Burn Care Quality Platform Analysis. Journal Of Burn Care & Research 2025, iraf087. PMID: 40394868, DOI: 10.1093/jbcr/iraf087.Peer-Reviewed Original ResearchTotal body surface areaNational estimatesIncidence rateOdds of discharge homeHome oxygen therapyTargeted prevention strategiesOxygen therapyBurn admissionsInhalation injuryIncidence of admissionPublic health problemTotal body surface area burnHome oxygen usePoisson regressionInjury characteristicsInjury descriptionInpatient mortalityPrevention strategiesBody surface areaInpatient outcomesDischarged homeHealth problemsNational averagePatient demographicsAnnual increaseState-Specific Incidence of Endometrial Cancer in the U.S. by Histologic Subtype Corrected for Hysterectomy Prevalence, 2010 to 2019.
Clarke M, Fisher J, Wentzensen N, Wijayabahu A, Arend R, Jones R, Erickson B. State-Specific Incidence of Endometrial Cancer in the U.S. by Histologic Subtype Corrected for Hysterectomy Prevalence, 2010 to 2019. Cancer Epidemiology Biomarkers & Prevention 2025, of1-of8. PMID: 40392197, DOI: 10.1158/1055-9965.epi-25-0057.Peer-Reviewed Original ResearchEndometrial cancer incidence ratesCancer incidence ratesHysterectomy prevalenceNon-endometrioid cancersIncidence rateNorth American Association of Central Cancer RegistriesBehavioral Risk Factor Surveillance SystemIncidence rates of endometrial cancerIncident endometrial cancer casesRisk Factor Surveillance SystemHysterectomy-corrected ratesCancer control effortsCentral Cancer RegistryEndometrial cancerRates of endometrial cancerEndometrial cancer incidenceNorth American AssociationEndometrial cancer ratesHysterectomy prevalence dataEndometrial cancer casesIncidence of endometrial cancerGeographic risk factorsCancer overallCancer RegistryCancer incidenceUsing geospatial analysis to describe the association between active tick surveillance data and clinical cases of anaplasmosis in Connecticut
Desiato J, Chan G, Palmeri M, Cantoni J, Cozens D, Linske M, Brackney D, Stafford K, Banach D. Using geospatial analysis to describe the association between active tick surveillance data and clinical cases of anaplasmosis in Connecticut. Journal Of Medical Entomology 2025, tjaf055. PMID: 40341955, DOI: 10.1093/jme/tjaf055.Peer-Reviewed Original ResearchDepartment of Public HealthConnecticut Department of Public HealthCases of anaplasmosisClinical cases of anaplasmosisIncidence ratePublic healthSurveillance dataPublic health interventionsPotential associationI. scapularisHealth interventionsTick surveillance dataConnecticut Agricultural Experiment StationIdentified geographic areasAgricultural Experiment StationEvaluate potential associationsIxodes scapularis ticksBacterium Anaplasma phagocytophilumPrevalence dataActive tick surveillanceClinical casesQuesting I. scapularisSpearman rank correlationIncreased riskAnaplasma phagocytophilumTrends in Cancer Incidence and Mortality Rates in Early-Onset and Older-Onset Age Groups in the United States, 2010-2019.
Shiels M, Haque A, Berrington de González A, Camargo M, Clarke M, Davis Lynn B, Engels E, Freedman N, Gierach G, Hofmann J, Jones R, Loftfield E, Sinha R, Morton L, Chanock S. Trends in Cancer Incidence and Mortality Rates in Early-Onset and Older-Onset Age Groups in the United States, 2010-2019. Cancer Discovery 2025, of1-of14. PMID: 40338148, DOI: 10.1158/2159-8290.cd-24-1678.Peer-Reviewed Original ResearchSerotype specific pneumococcal vaccine effectiveness in children with sickle cell disease: A two-decade analysis
Zhang Z, Yildirim M, Keskinocak P, Dasthagirisaheb Y, Hinderstein S, Tran K, Crockett M, Burns M, Johnson H, Popstefanija M, Madoff L, Pelton S, Yildirim I. Serotype specific pneumococcal vaccine effectiveness in children with sickle cell disease: A two-decade analysis. Vaccine 2025, 56: 127193. PMID: 40318350, DOI: 10.1016/j.vaccine.2025.127193.Peer-Reviewed Original ResearchIncidence rate ratiosInvasive pneumococcal diseaseSickle cell diseaseIncidence ratePost-PCV13 periodCalculated incidence ratesValency vaccinesVaccine effectivenessPneumococcal diseaseHealthy childrenRates of invasive pneumococcal diseasePopulation-basedCell diseaseHealth conditionsRate ratiosNon-PCV13 serotypesPneumococcal vaccine effectivenessVulnerable populationsBootstrapping resamplingIncreased riskHigher IRNon-PCV13Genetic hematological diseasesHematological diseasesVaccine formulationsPrimary Tumors of the Brain and Central Nervous System in Adults and Children in Sub-Saharan Africa: Protocol for a Scoping Review
Al-Fikri A, Alhammadi M, Arum C, Kaur M, Del Biondo K, Bani I, Mudenda V, Vermund S. Primary Tumors of the Brain and Central Nervous System in Adults and Children in Sub-Saharan Africa: Protocol for a Scoping Review. JMIR Research Protocols 2025, 14: e66978. PMID: 40273436, PMCID: PMC12062764, DOI: 10.2196/66978.Peer-Reviewed Original ResearchConceptsINTERNATIONAL REGISTERED REPORT IDENTIFIERInternational Agency for Research on CancerSub-Saharan AfricaScoping ReviewIndependent reviewersIncidence rateCentral nervous systemFull-text screeningLow-resource settingsCentral nervous system cancerSub-SaharanNeurosurgery facilityPRISMA-ScRLow incidence rateGlobal health organizationsEvidence synthesisService gapsReviewed titlesGrey literaturePRISMA-PAbstract screeningTreatment of CNS tumorsCentral nervous system tumorsOvid MEDLINEEligibility criteriaIncidence of Frailty, Dementia, and Disability Among Community‐Living Older Americans According to County‐Level Disadvantage
Wang Y, Zang E, Davis‐Plourde K, Vander Wyk B, Gill T, Becher R. Incidence of Frailty, Dementia, and Disability Among Community‐Living Older Americans According to County‐Level Disadvantage. Journal Of The American Geriatrics Society 2025, 73: 1847-1856. PMID: 40196885, DOI: 10.1111/jgs.19465.Peer-Reviewed Original ResearchConceptsNational Health and Aging Trends StudyActivities of daily living disabilityActivities of daily livingIncidence of frailtySocial determinants of healthOlder personsOlder AmericansContextual disadvantageAge- and sex-adjusted HRDisadvantaged countiesDeterminants of healthSex-adjusted HRNationally representative longitudinal studyRepresentative longitudinal studyCommunity-livingDaily livingClinically Meaningful OutcomesTrends StudyGeriatric conditionsNo prior studiesNational incidenceIncidence rateDementiaFrailtyCounty-level649 National Estimates and Outcomes for Oxygen Therapy Injuries—a BCQP Analysis
Sheckter C, Phillips B, Klas K, Coffey R, Savetamal A, Wibbenmeyer L. 649 National Estimates and Outcomes for Oxygen Therapy Injuries—a BCQP Analysis. Journal Of Burn Care & Research 2025, 46: s214-s214. PMCID: PMC11958026, DOI: 10.1093/jbcr/iraf019.278.Peer-Reviewed Original ResearchInjury descriptionIncidence rateWhite raceSmoke inhalation injuryBurn centerInhalation injuryFree-text fieldsChronic obstructive pulmonary diseaseChronic respiratory illnessText fieldsObstructive pulmonary diseasePoisson regressionAmerican Burn AssociationInjury characteristicsNational estimatesPrevention effortsInpatient mortalityResponder cohortInpatient outcomesLogistic regressionPrimary payerNational averageWhite patientsYears median ageNational databaseIs Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis
Alani O, Wang D, Wahood S, Obagi S, Dasilva D, Zirwas M, Galimberti F, Bunick C. Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis. Journal Of Drugs In Dermatology 2025, 24: 530-533. PMID: 40327575, DOI: 10.36849/jdd.9049.Peer-Reviewed Original ResearchConceptsUPA-treated patientsVenous thromboembolismVenous thromboembolism ratesAdverse cardiovascular eventsChronic inflammatory diseaseAtopic dermatitisMACE rateCardiovascular eventsClinical trialsInflammatory diseasesLong-term MACE rateIncidence rateImpact of upadacitinibPersistent systemic inflammationRisk of cardiovascular diseaseSystemic inflammationAD-related inflammationLower MACEBackground incidence ratesUpadacitinibJAK1 inhibitionPatientsThromboembolismCardiovascular diseaseMACESocioeconomic and demographic disparities in the impact of digestive diseases in the middle East and North Africa (MENA) region
Al Ta’ani O, Al-Ajlouni Y, Lahoud C, Almasaid S, Alhalalmeh Y, Oweis Z, Danpanichkul P, Baidoun A, Alsakarneh S, Dahiya D, Njei B. Socioeconomic and demographic disparities in the impact of digestive diseases in the middle East and North Africa (MENA) region. International Journal For Equity In Health 2025, 24: 85. PMID: 40148874, PMCID: PMC11951616, DOI: 10.1186/s12939-025-02448-9.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsEstimated annual percentage changeSocio-demographic IndexAge-standardized incidence rateDisability-adjusted life year ratesGlobal Burden of DiseaseMiddle East and North AfricaGender Inequality IndexHuman Development IndexMiddle East and North Africa regionImpact of socioeconomic disparitiesIncidence rateAge-standardized mortalityAge-standardized ratesAnnual percentage changePercentage changeInfluence disease burdenBurden of DDBurden of diseasePublic health challengeHighest incidence rateSocioeconomic disparitiesDD incidenceTargeted interventionsNorth AfricaDeucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials
Armstrong A, Kircik L, Stein Gold L, Strober B, De Oliveira C, Vaile J, Jou Y, Daamen C, Scharnitz T, Lebwohl M. Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials. Dermatology And Therapy 2025, 15: 1025-1035. PMID: 40113724, PMCID: PMC11971090, DOI: 10.1007/s13555-025-01362-w.Peer-Reviewed Original ResearchLaboratory adverse eventsLaboratory parametersAdverse eventsLong-term extensionPlaque psoriasisModerate to severe plaque psoriasisSevere plaque psoriasisDouble-blind trialTyrosine kinase 2 inhibitorTreatment of adultsJanus kinaseSystemic therapyClinically meaningful changeDeucravacitinibPsoriasis trialsPatientsIncidence rateHigh gradePlaceboApremilastMeaningful changePsoriasisTrialsGradePhase 3Mapping the viral battlefield: SARS-CoV-2 infection dynamics among healthcare workers in Brazil
Gasparoto A, Graeff S, de Souza Santiago W, da Silva D, dos Santos T, Paulino L, Fava W, Reis F, Stutz C, de Oliveira França A, Guerrero Moureau A, Montalbano C, Lemos E, Gonçalves C, Júnior C, Dallacqua R, Croda J, Lorenz A, Souza C, Martins T, da Silva K, Ferreira A, Negri A, Paniago A, Motta-Castro A, Venturini J, da Costa Marques A, do Valle Leone de Oliveira S. Mapping the viral battlefield: SARS-CoV-2 infection dynamics among healthcare workers in Brazil. Human Resources For Health 2025, 23: 8. PMID: 39934893, PMCID: PMC11817727, DOI: 10.1186/s12960-024-00968-z.Peer-Reviewed Original ResearchConceptsHealthcare workersReferral hospitalSARS-CoV-2 infectionNon-referral hospitalsRisk factorsCOVID-19 careHighest incidence rateCOVID-19 referral centerCOVID-19 referral hospitalsPositive diagnosis of COVID-19SARS-CoV-2Being maleIncidence rateTertiary hospitalCohort studyHospitalization ratesSARS-CoV-2 viral infectionGeneral populationCOVID-19HealthcareHospital environmentDiagnosis of COVID-19Transmission of SARS-CoV-2 infectionReferral centerHospitalIncomplete Ascertainment of Mortality in a Nationally Representative Longitudinal Study of Community-Living Older Americans
Gill T, Liang J, Vander Wyk B, Leo-Summers L, Wang Y, Becher R, Davis-Plourde K. Incomplete Ascertainment of Mortality in a Nationally Representative Longitudinal Study of Community-Living Older Americans. The Journals Of Gerontology Series A 2025, glaf014. PMID: 39823281, DOI: 10.1093/gerona/glaf014.Peer-Reviewed Original ResearchNational Health and Aging Trends StudyAscertainment of mortalityIncomplete ascertainmentLongitudinal studies of older personsStudy of older personsNationally representative longitudinal studyIncidence rate ratiosLoss to follow-upMortality incidence ratesYear of deathLongitudinal studyRepresentative longitudinal studyCommunity-livingTrends StudyOlder personsRecommended strategiesMedicare dataRate ratiosCumulative mortality rateIncidence rateResults of longitudinal analysesAscertainmentEvaluate mortalityLongitudinal analysisDecedentsSafety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo M, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years. JAMA Dermatology 2025, 161: 56-66. PMID: 39602111, PMCID: PMC11736510, DOI: 10.1001/jamadermatol.2024.4688.Peer-Reviewed Original ResearchLong-term extension trialsExposure-adjusted incidence ratesSevere plaque psoriasisLong-term extensionModerate to severe plaque psoriasisAdverse eventsPlaque psoriasisDouble-blind phase 3 trialStatic Physician's Global Assessment scoreDiscontinuation due to adverse eventsDay 1Physician Global Assessment scoreIncidence rateEffective long-term treatmentUpper respiratory tract infectionClinical response rateGlobal assessment scorePhase 3 trialRespiratory tract infectionsWeeks of treatmentYear of treatmentLong-term treatmentAdverse cardiovascular eventsLong-term safetyCumulative period
2024
Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience
Patel R, Jin C, Jaber D, Casasanta N, Jain M, Fu W, Wu C, Moshier E, Tiersten A. Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience. Clinical Breast Cancer 2024, 25: 283-290. PMID: 39837695, DOI: 10.1016/j.clbc.2024.12.020.Peer-Reviewed Original ResearchConceptsLobular carcinoma in situDuctal carcinoma in situLow dose tamoxifenCarcinoma in situAtypical hyperplasiaBreast cancer preventionLog-binomial modelsRetrospective chart review of womenPoison regression modelsChart review of womenIncidence rate of AEFrequency of adverse eventsReview of womenCompare adverse event ratesRetrospective chart reviewHigh-risk lesionsAdverse event ratesCancer preventionIncidence rateAromatase inhibitorsAtypical lesionsAdverse eventsRegression modelsDisease characteristicsHyperplasiaOccurrence of Opioid-Related Neurocognitive Symptoms Associated With Long-term Opioid Therapy
León C, Sung M, Reisman J, Liu W, Kerns R, Gordon K, Mitra A, Kwon S, Yu H, Becker W, Li W. Occurrence of Opioid-Related Neurocognitive Symptoms Associated With Long-term Opioid Therapy. The Clinical Journal Of Pain 2024, 41: e1266. PMID: 39682036, PMCID: PMC11729567, DOI: 10.1097/ajp.0000000000001266.Peer-Reviewed Original ResearchLong-term opioid therapyElectronic health recordsIncidence rate ratiosOpioid-related harmsSubstance use disordersNeurocognitive symptomsHazard ratioPatients prescribed long-term opioid therapyVeterans Health AdministrationCalculated incidence ratesAssociated with increased likelihoodChronic obstructive pulmonary diseasePost-traumatic stress disorderHealth recordsProportional hazards modelRetrospective cohort studyObstructive pulmonary diseaseHealth AdministrationRate ratiosIncidence rateCohort studyTraumatic brain injuryClinical notesExtract dataHazards modelValidation and epidemiologic definition of the novel steatotic liver disease nomenclature in a national United States cohort with cirrhosis
Mezzacappa C, Ochoa-Allemant P, Serper M, Taddei T, John B, Kaplan D, Mahmud N. Validation and epidemiologic definition of the novel steatotic liver disease nomenclature in a national United States cohort with cirrhosis. Clinical Gastroenterology And Hepatology 2024 PMID: 39689774, PMCID: PMC12167392, DOI: 10.1016/j.cgh.2024.10.035.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseCardiometabolic risk factorsAlcohol use disorderSteatotic liver diseaseLiver diseaseLow high-density lipoproteinChild-Turcotte-Pugh classIncidence rateIncident hepatocellular carcinomaIncreased alcohol intakeAlcohol useClinically relevant definitionAll-Cause MortalityHigher hazard of mortalityNational cohort of veteransUnited States cohortCohort of veteransAcute cardiac eventsHigh-density lipoproteinHazard of mortalityHazardous alcohol useAlcohol intakeCardiac eventsAlcohol exposureHepatocellular carcinoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply